Taiwanese Journal of Obstetrics and Gynecology
Volume 50, Issue 1 , Pages 2-10 , March 2011

Update on management of ovarian hyperstimulation syndrome

  • Chin-Der Chen

      Affiliations

    • Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan
    • National Taiwan University College of Medicine, Taipei, Taiwan
    • ,
  • Ming-Ying Wu

      Affiliations

    • Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan
    • National Taiwan University College of Medicine, Taipei, Taiwan
    • ,
  • Kuang-Han Chao

      Affiliations

    • Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan
    • National Taiwan University College of Medicine, Taipei, Taiwan
    • ,
  • Yih-Ron Lien

      Affiliations

    • Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan
    • National Taiwan University College of Medicine, Taipei, Taiwan
    • ,
  • Shee-Uan Chen

      Affiliations

    • Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan
    • National Taiwan University College of Medicine, Taipei, Taiwan
    • ,
  • Yu-Shih Yang

      Affiliations

    • Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan
    • National Taiwan University College of Medicine, Taipei, Taiwan
    • Corresponding Author InformationCorresponding author. Department of Obstetrics and Gynecology, National Taiwan University Hospital, 8 Chung-Shan South Road, Taipei, Taiwan.

,Accepted 7 September 2010.

References 

  1. Madill JJ, Mullen NB, Harrison BP. Ovarian hyperstimulation syndrome: a potentially fatal complication of early pregnancy. J Emerg Med. 2008;35:283–286
  2. Chen CD, Wu MY, Chao KH, Chen SU, Ho HN, Yang YS. Serum estradiol level and oocyte number in predicting severe ovarian hyperstimulation syndrome. J Formos Med Assoc. 1997;96:829–834
  3. Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril. 2010;94:389–400
  4. Polishuk WZ, Schenker JG. Ovarian overstimulation syndrome. Fertil Steril. 1969;20:443–450
  5. Goldsman MP, Pedram A, Dominguez CE, Ciuffardi I, Levin E, Asch RH. Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril. 1995;63:268–272
  6. Chen SU, Chen CD, Yang YS. Ovarian hyperstimulation syndrome (OHSS): new strategies of prevention and treatment. J Formos Med Assoc. 2008;107:509–512
  7. Chen SU, Chou CH, Lee H, Ho CH, Lin CW, Yang YS. Lysophosphatidic acid up-regulates expression of interleukin-8 and -6 in granulosa-lutein cells through its receptors and nuclear factor-κB dependent pathways: implications for angiogenesis of corpus luteum and ovarian hyperstimulation syndrome. J Clin Endocrinol Metab. 2008;93:935–943
  8. Chen SU, Chen RJ, Shieh JY, Chou CH, Lin CW, Lu HF, et al. Human chorionic gonadotropin up-regulates expression of myeloid cell leukemia-1 protein in human granulosa-lutein cells: implication of corpus luteum rescue and ovarian hyperstimulation syndrome. J Clin Endocrinol Metab. 2010;95:3982–3992
  9. Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA. 1993;269:1829–1835
  10. McClure N, Healy DL, Rogers PAW, Sullivan J, Beaton L, Haning RV, et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet. 1994;344:235–236
  11. Wang TH, Horng SG, Chang CL, Wu HM, Tsai YJ, Wang HS, et al. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab. 2002;87:3300–3308
  12. Chen CD, Chen HF, Lu HF, Chen SU, Ho HN, Yang YS. Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. Hum Reprod. 2000;15:1037–1042
  13. Chen CD, Wu MY, Chen HF, Chen SU, Ho HN, Yang YS. Prognostic importance of serial cytokine changes in ascites and pleural effusion in women with severe ovarian hyperstimulation syndrome. Fertil Steril. 1999;72:286–292
  14. Chen SU, Chou CH, Lin CW, Lee H, Wu JC, Lu HF, et al. Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their common pathways. Hum Reprod. 2010;25:757–767
  15. Chen CD, Wu MY, Chen HF, Chen SU, Ho HN, Yang YS. Relationships of serum pro-inflammatory cytokines and vascular endothelial growth factor with liver dysfunction in severe ovarian hyperstimulation syndrome. Hum Reprod. 2000;15:66–71
  16. Chan WS. The ‘ART’ of thrombosis: a review of arterial and venous thrombosis in assisted reproductive technology. Curr Opin Obstet Gynecol. 2009;21:207–218
  17. Carlotti AP, Carvalho WB. Abdominal compartment syndrome: a review. Pediatr Crit Care Med. 2009;10:115–120
  18. Selgas R, Del Peso G, Bajo MA. Intra-abdominal hypertension favors ascites. Perit Dial Int. 2010;30:156–157
  19. Cheatham ML. Abdominal compartment syndrome: pathophysiology and definitions. Scand J Trauma Resusc Emerg Med. 2009;17:10
  20. Harman PK, Kron IL, McLachlan HD, Freedlender AE, Nolan SP. Elevated intra-abdominal pressure and renal function. Ann Surg. 1982;196:594–597
  21. Vlahos NF, Gregoriou O. Prevention and management of ovarian hyperstimulation syndrome. Ann N Y Acad Sci. 2006;1092:247–264
  22. Hsieh MJ, Tsao TC, Cheng PJ. Ovarian hyperstimulation syndrome with minimal ascites and massive pleural effusion: report of a case. J Formos Med Assoc. 1994;93:882–884
  23. Tang HH, Tsai YC, Kang CY, Chung MT, Loo TC, Huang KF. Atypical ovarian hyperstimulation syndrome with isolated pleural effusion but without ascites or hemoconcentration. Taiwan J Obstet Gynecol. 2007;46:180–182
  24. Beji O, Brahmi N, Thabet H, Mokline A, Abidi N, Blel Y, et al. Compressive pleural effusion after ovarian hyperstimulation syndrome—a case report and review. Fertil Steril. 2008;89:1826.e1–1826.e3
  25. Malbrain M, Cheatham M, Kirkpatrick A, Sugrue M, Parr M, De Waele J, et al. Results from the international conference of experts on intra-abdominal hypertension and abdominal compartment syndrome. I. Definitions. Intensive Care Med. 2006;32:1722–1732
  26. Cheatham ML. Abdominal compartment syndrome. Curr Opin Crit Care. 2009;15:154–162
  27. Grossman LC, Michalakis KG, Browne H, Payson MD, Segars JH. The pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndrome. Fertil Steril. 2010;94:1392–1398
  28. Cil T, Tummon IS, House AA, Taylor B, Hooker G, Franklin J, et al. A tale of two syndromes: ovarian hyperstimulation and abdominal compartment. Hum Reprod. 2000;15:1058–1060
  29. Maslovitz S, Jaffa A, Eytan O, Wolman I, Many A, Lessing JB, et al. Renal blood flow alteration after paracentesis in women with ovarian hyperstimulation. Obstet Gynecol. 2004;104:321–326
  30. Golan A, Ron-El R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989;44:430–440
  31. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril. 1992;58:249–261
  32. Golan A, Weissman A. A modern classification of OHSS. Reprod Biomed Online. 2009;19:28–32
  33. Practice Committee of American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril. 2003;80:1309–1314
  34. Practice Committee of American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril. 2008;90:S188–S193
  35. Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril. 2000;73:901–907
  36. Lee KH, Kim SH, Jee BC, Kim YJ, Suh CS, Kim KC, et al. Comparison of clinical characteristics between early and late patterns in hospitalized patients with ovarian hyperstimulation syndrome. Fertil Steril. 2010;93:2274–2280
  37. Chen CD, Chao KH, Yang JH, Chen SU, Ho HN, Yang YS. Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimulation syndrome. Fertil Steril. 2003;80:86–90
  38. Chen CD, Wu MY, Yang JH, Chen SU, Ho HN, Yang YS. Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome. Fertil Steril. 1997;68:287–291
  39. Whelan JG, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril. 2000;73:883–896
  40. Cheatham M, Malbrain M, Kirkpatrick A, Sugrue M, Parr M, De Waele J, et al. Results from the international conference of experts on intra-abdominal hypertension and abdominal compartment syndrome. II. Recommendations. Intensive Care Med. 2007;33:951–962
  41. Cheatham M. Nonoperative management of intraabdominal hypertension and abdominal compartment syndrome. World J Surg. 2009;33:1116–1122
  42. Royal College of Obstetricians and Gynaecologists (RCOG). The management of ovarian hyperstimulation syndrome. London (UK): RCOG; 2006;pp. 11. (Green-top guideline; no. 5)
  43. Shrivastav P, Nadkarni P, Craft I. Day care management of severe ovarian hyperstimulation syndrome avoids hospitalization and morbidity. Hum Reprod. 1994;9:812–814
  44. Lincoln SR, Opsahl MS, Blauer KL, Black SH, Schulman JD. Aggressive outpatient treatment of ovarian hyperstimulation syndrome with ascites using transvaginal culdocentesis and intravenous albumin minimizes hospitalization. J Assist Reprod Genet. 2002;19:159–163
  45. Smith LP, Hacker MR, Alper MM. Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis. Fertil Steril. 2009;92:1953–1959
  46. Fluker MR, Copeland JE, Yuzpe AA. An ounce of prevention: outpatient management of the ovarian hyperstimulation syndrome. Fertil Steril. 2000;73:821–824
  47. Csokmay JM, Yauger BJ, Henne MB, Armstrong AY, Queenan JT, Segars JH. Cost analysis model of outpatient management of ovarian hyperstimulation syndrome with paracentesis: “Tap early and often” versus hospitalization. Fertil Steril. 2010;93:167–173
  48. Victorino GP, Newton CR, Curran B. Effect of hypertonic saline on microvascular permeability in the activated endothelium. J Surg Res. 2003;112:79–83
  49. Strandvik GF. Hypertonic saline in critical care: a review of the literature and guidelines for use in hypotensive states and raised intracranial pressure. Anaesthesia. 2009;64:990–1003
  50. Tan TS, Tan KH, Ng HP, Loh MW. The effects of hypertonic saline solution (7.5%) on coagulation and fibrinolysis: an in vitro assessment using thromboelastography. Anaesthesia. 2002;57:644–648
  51. Ayus JC, Krothapalli RK, Arieff AI. Treatment of symptomatic hyponatremia and its relation to brain damage. A prospective study. N Engl J Med. 1987;317:1190–1195
  52. Hew-Butler T, Almond C, Ayus JC, Dugas J, Meeuwisse W, Noakes T, et al. Consensus statement of the 1st International Exercise-Associated Hyponatremia Consensus Development Conference, Cape Town, South Africa 2005. Clin J Sport Med. 2005;15:208–213
  53. Kolsen-Petersen JA, Nielsen JO, Tonnesen E. Acid base and electrolyte changes after hypertonic saline (7.5%) infusion: a randomized controlled clinical trial. Scand J Clin Lab Invest. 2005;65:13–22
  54. Oda JMD, Ueyama MMD, Yamashita KMD, Inoue TMD, Noborio MMD, Ode YMD, et al. Hypertonic lactated saline resuscitation reduces the risk of abdominal compartment syndrome in severely burned patients. J Trauma. 2006;60:64–71
  55. Chen CD, Yang JH, Chao KH, Chen SU, Ho HN, Yang YS. Effects of repeated abdominal paracentesis on uterine and intraovarian haemodynamics and pregnancy outcome in severe ovarian hyperstimulation syndrome. Hum Reprod. 1998;13:2077–2081
  56. Ozgun MT, Batukan C, Oner G, Uludag S, Aygen EM, Sahin Y. Removal of ascites up to 7.5 liters on one occasion and 45 liters in total may be safe in patients with severe ovarian hyperstimulation syndrome. Gynecol Endocrinol. 2008;24:656–658
  57. Cabrera J, Falcon L, Gorriz E, Pardo MD, Granados R, Quinones A, et al. Abdominal decompression plays a major role in early postparacentesis haemodynamic changes in cirrhotic patients with tense ascites. Gut. 2001;48:384–389
  58. Al-Ramahi M, Leader A, Claman P, Spence J. A novel approach to the treatment of ascites associated with ovarian hyperstimulation syndrome. Hum Reprod. 1997;12:2614–2616
  59. Abuzeid MI, Nassar Z, Massaad Z, Weiss M, Ashraf M, Fakih M. Pigtail catheter for the treatment of ascites associated with ovarian hyperstimulation syndrome. Hum Reprod. 2003;18:370–373
  60. Nelson SM. Prophylaxis of VTE in women—during assisted reproductive techniques. Thromb Res. 2009;123:S8–S15
  61. Ou YC, Kao YL, Lai SL, Kung FT, Huang FJ, Chang SY, et al. Thromboembolism after ovarian stimulation: successful management of a woman with superior sagittal sinus thrombosis after IVF and embryo transfer: case report. Hum Reprod. 2003;18:2375–2381
  62. Ferraretti AP, Gianaroli L, Diotallevi L, Festi C, Trounson A. Dopamine treatment for severe ovarian hyperstimulation syndrome. Hum Reprod. 1992;7:180–183
  63. Tsunoda T, Shibahara H, Hirano Y, Suzuki T, Fujiwara H, Takamizawa S, et al. Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine. Gynecol Endocrinol. 2003;17:281–286
  64. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med. 2001;7:569–574
  65. Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, Novella-Maestre E, Alonso-Muriel I, Sanchez-Criado J, et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology. 2006;147:5400–5411
  66. Alvarez C, Marti-Bonmati L, Novella-Maestre E, Sanz R, Gomez R, Fernandez-Sanchez M, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab. 2007;92:2931–2937
  67. Alvarez C, Alonso-Muriel I, Garcia G, Crespo J, Bellver J, Simon C, et al. Implantation is apparently unaffected by the dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod. 2007;22:3210–3214
  68. Carizza C, Abdelmassih V, Abdelmassih S, Ravizzini P, Salgueiro L, Salgueiro PT, et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online. 2008;17:751–755
  69. Youssef MAFM, van Wely M, Hassan MA, Al-Inany HG, Mochtar M, Khattab S, et al. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum Reprod Update. 2010;16:459–466
  70. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol. 2007;6:826–829
  71. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007;356:39–46
  72. Busso C, Fernandez-Sanchez M, Garcia-Velasco JA, Landeras J, Ballesteros A, Munoz E, et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Hum Reprod. 2010;25:995–1004
  73. Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update. 2006;12:651–671
  74. Friden BE, Nilsson L. Gonadotrophin-releasing hormone-antagonist luteolysis during the preceding mid-luteal phase is a feasible protocol in ovarian hyperstimulation before in vitro fertilization. Acta Obstet Gynecol Scand. 2005;84:812–816
  75. Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Kolibianakis EM. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist. Reprod Biomed Online. 2007;15:408–412
  76. Rollene NL, Amols MH, Hudson SBA, Coddington CC. Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series. Fertil Steril. 2009;92:1169.e15–1169.e17
  77. Moses MA, Harper J, Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med. 2006;354:2621–2622
  78. Fainaru O, Adini I, Benny O, Bazinet L, Pravda E, D'Amato R, et al. Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability. FASEB J. 2008;22:3728–3735
  79. Fainaru O, Hornstein MD, Folkman J. Doxycycline inhibits vascular leakage and prevents ovarian hyperstimulation syndrome in a murine model. Fertil Steril. 2009;92:1701–1705

PII: S1028-4559(11)00015-5

doi: 10.1016/j.tjog.2011.01.014

Taiwanese Journal of Obstetrics and Gynecology
Volume 50, Issue 1 , Pages 2-10 , March 2011

Article Tools

* Image Usage & Resolution